Pulmonary hypertension is a clinical syndrome that may include multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. Pulmonary hypertension secondary to left heart disease is the prevalent clinical condition and accounts for two-thirds of all cases. Type 2 diabetes mellitus, which affects about 422 million adults world- wide, has emerged as an independent risk factor for the development of pulmonary hypertension in patients with left heart failure. While a correct diagnosis of pulmonary hypertension secondary to left heart disease requires invasive hemodynamic evaluation through right heart catheterization, several scores integrating clinical and echocardiographic parameters have been proposed to discriminate pre- and post-capillary types of pulmonary hypertension. Despite new emerging evidence on the pathophysiological mechanisms behind the effects of diabetes in patients with pre- and/or post-capillary pulmonaryhypertension, no specific drug has been yet approved for this group of patients. In the last few years, the attention has been focused on the role of antidiabetic drugs in patients with pulmonary hypertension secondary to left heart failure, both in ani- mal models and in clinical trials. The aim of the present review is to highlight the links emerged in the recent years between diabetes and pre- and/or post-capillary pulmonary hypertension and new perspectives for antidiabetic drugs in this setting.
Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension / Luongo, Federico; Miotti, Cristiano; Scoccia, Gianmarco; Papa, Silvia; Manzi, Giovanna; Cedrone, Nadia; Toto, Federica; Malerba, Claudia; Papa, Gennaro; Caputo, Annalisa; Manguso, Giulia; Adamo, Francesca; Vizza, Carmine Dario; Badagliacca, Roberto. - In: HEART FAILURE REVIEWS. - ISSN 1382-4147. - (2022). [10.1007/s10741-021-10208-4]
Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension
Luongo, FedericoPrimo
;Miotti, CristianoSecondo
;Scoccia, Gianmarco;Papa, Silvia;Manzi, Giovanna;Toto, Federica;Malerba, Claudia;Papa, Gennaro;Caputo, Annalisa;Manguso, Giulia;Adamo, Francesca;Carmine, Dario VizzaPenultimo
;Badagliacca, Roberto
Ultimo
2022
Abstract
Pulmonary hypertension is a clinical syndrome that may include multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. Pulmonary hypertension secondary to left heart disease is the prevalent clinical condition and accounts for two-thirds of all cases. Type 2 diabetes mellitus, which affects about 422 million adults world- wide, has emerged as an independent risk factor for the development of pulmonary hypertension in patients with left heart failure. While a correct diagnosis of pulmonary hypertension secondary to left heart disease requires invasive hemodynamic evaluation through right heart catheterization, several scores integrating clinical and echocardiographic parameters have been proposed to discriminate pre- and post-capillary types of pulmonary hypertension. Despite new emerging evidence on the pathophysiological mechanisms behind the effects of diabetes in patients with pre- and/or post-capillary pulmonaryhypertension, no specific drug has been yet approved for this group of patients. In the last few years, the attention has been focused on the role of antidiabetic drugs in patients with pulmonary hypertension secondary to left heart failure, both in ani- mal models and in clinical trials. The aim of the present review is to highlight the links emerged in the recent years between diabetes and pre- and/or post-capillary pulmonary hypertension and new perspectives for antidiabetic drugs in this setting.File | Dimensione | Formato | |
---|---|---|---|
Luongo_Future perspective in_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
946.63 kB
Formato
Adobe PDF
|
946.63 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.